Danske Bank A S Invests $133.05 Million in Gilead Sciences, Inc. $GILD

Danske Bank A S acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,198,637 shares of the biopharmaceutical company’s stock, valued at approximately $133,049,000.

Several other large investors have also bought and sold shares of the stock. Corundum Trust Company INC acquired a new position in Gilead Sciences during the 3rd quarter worth about $26,000. Howard Hughes Medical Institute acquired a new stake in shares of Gilead Sciences in the second quarter valued at about $30,000. MTM Investment Management LLC raised its position in shares of Gilead Sciences by 176.0% during the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 176 shares during the last quarter. Kilter Group LLC acquired a new position in shares of Gilead Sciences in the second quarter worth approximately $33,000. Finally, Millstone Evans Group LLC lifted its stake in shares of Gilead Sciences by 58.7% in the third quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 118 shares during the period. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Trading Down 0.6%

Shares of GILD stock opened at $144.40 on Wednesday. Gilead Sciences, Inc. has a fifty-two week low of $93.37 and a fifty-two week high of $157.29. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55. The stock has a 50 day simple moving average of $141.62 and a two-hundred day simple moving average of $127.41. The company has a market cap of $179.26 billion, a P/E ratio of 21.33, a PEG ratio of 1.90 and a beta of 0.37.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The firm had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same period in the prior year, the business earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be issued a $0.82 dividend. The ex-dividend date is Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a yield of 2.3%. Gilead Sciences’s dividend payout ratio is 48.45%.

Insider Activity at Gilead Sciences

In other news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $144.23, for a total transaction of $432,690.00. Following the transaction, the insider owned 131,779 shares of the company’s stock, valued at $19,006,485.17. This represents a 2.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total value of $617,500.00. Following the completion of the sale, the director directly owned 8,920 shares of the company’s stock, valued at $1,101,620. The trade was a 35.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 309,280 shares of company stock valued at $44,068,850. Company insiders own 0.27% of the company’s stock.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Arcellx / takeover-related coverage — reports note a Gilead-related takeover theme that drove a big one‑day move in a small biotech (Arcellx). M&A activity or strategic deals in cell therapy could be viewed positively for Gilead’s pipeline expansion and long-term growth prospects. This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal
• Neutral Sentiment: Unusual options activity flagged by market scanners — Barchart/MSN highlighted Gilead among mega‑caps with unusual options flows, which can signal speculative interest or hedging by institutions but is ambiguous for directional bias. Monitor option volumes and put/call skew for confirmation. 2 Mega-Cap Nasdaq Stocks with Unusual Options Activity: What to Watch
• Negative Sentiment: Insider sale — Johanna Mercier sold 3,000 shares at an average $144.23 on Mar 16 (disclosed to the SEC). Insider selling can be interpreted negatively by investors even if part of routine diversification or pre-set plans. Insider Sale – Johanna Mercier (SEC Filing)
• Negative Sentiment: Insider sale — CFO Andrew D. Dickinson also sold 3,000 shares at an average $144.23 on Mar 16. A sale by the CFO can draw extra attention from investors and may weigh on sentiment in the near term. Insider Sale – Andrew D. Dickinson (SEC Filing)

Analyst Ratings Changes

Several analysts recently commented on the company. Leerink Partners upped their target price on Gilead Sciences from $146.00 to $148.00 and gave the company an “outperform” rating in a report on Wednesday, February 11th. Bank of America set a $162.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday, February 11th. Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $160.00 price objective on shares of Gilead Sciences in a research note on Wednesday, February 11th. Mizuho increased their price objective on shares of Gilead Sciences from $140.00 to $170.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 18th. Finally, The Goldman Sachs Group lifted their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock a “neutral” rating in a research note on Thursday, January 8th. Twenty-four investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and an average price target of $157.62.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.